Skip to main navigation Skip to search Skip to main content

Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: Results from the phase i KEYNOTE-001 study

  • Edward B. Garon
  • , Matthew D. Hellmann
  • , Naiyer A. Rizvi
  • , Enric Carcereny
  • , Natasha B. Leighl
  • , Myung Ju Ahn
  • , Joseph Paul Eder
  • , Ani S. Balmanoukian
  • , Charu Aggarwal
  • , Leora Horn
  • , Amita Patnaik
  • , Matthew Gubens
  • , Suresh S. Ramalingam
  • , Enriqueta Felip
  • , Jonathan W. Goldman
  • , Cathie Scalzo
  • , Erin Jensen
  • , Debra A. Kush
  • , Rina Hui
  • University of California at Los Angeles
  • Memorial Sloan-Kettering Cancer Center
  • Columbia University
  • Catalan Institute of Oncology Badalona
  • Princess Margaret Cancer Centre
  • Yale University
  • The Angeles Clinic and Research Institute
  • University of Pennsylvania
  • Vanderbilt University
  • South Texas Accelerated Research Therapeutics
  • University of California at San Francisco
  • Emory University
  • Vall d'Hebron Institute of Oncology
  • Merck
  • The University of Sydney

Research output: Contribution to journal › Article › peer-review

1072   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: Results from the phase i KEYNOTE-001 study'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology